$SKGR
SK Growth Opportunities Corp

2023 Q1 Form 10-Q Financial Statement

#000119312523143597 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $290.0K $40.00K
YoY Change 625.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $290.0K $40.00K
YoY Change 625.0%
Operating Profit -$292.1K -$37.03K
YoY Change 688.64%
Interest Expense $2.300M
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.301M $0.00
YoY Change
Pretax Income $2.010M -$40.00K
YoY Change -5125.0%
Income Tax
% Of Pretax Income
Net Earnings $2.009M -$37.03K
YoY Change -5524.12%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.08 $0.00
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $400.0K $200.0K
YoY Change 100.0%
Cash & Equivalents $373.3K $161.9K
Short-Term Investments
Other Short-Term Assets $500.0K
YoY Change
Inventory
Prepaid Expenses $464.5K
Receivables
Other Receivables
Total Short-Term Assets $837.8K $200.0K
YoY Change 318.9%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $219.9M
YoY Change
Other Assets $100.0K $400.0K
YoY Change -75.0%
Total Long-Term Assets $220.0M $400.0K
YoY Change 54912.23%
TOTAL ASSETS
Total Short-Term Assets $837.8K $200.0K
Total Long-Term Assets $220.0M $400.0K
Total Assets $220.9M $600.0K
YoY Change 36714.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $24.03K $0.00
YoY Change
Accrued Expenses $375.0K $300.0K
YoY Change 25.0%
Deferred Revenue
YoY Change
Short-Term Debt $5.200M $300.0K
YoY Change 1633.33%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.639M $600.0K
YoY Change 839.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.300M
YoY Change
Total Long-Term Liabilities $7.336M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.639M $600.0K
Total Long-Term Liabilities $7.336M $0.00
Total Liabilities $12.98M $600.0K
YoY Change 2062.5%
SHAREHOLDERS EQUITY
Retained Earnings -$11.94M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$11.93M -$45.86K
YoY Change
Total Liabilities & Shareholders Equity $220.9M $600.0K
YoY Change 36714.45%

Cashflow Statement

Concept 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $2.009M -$37.03K
YoY Change -5524.12%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$142.1K -$38.36K
YoY Change 270.42%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 200.3K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -142.1K -38.36K
Cash From Investing Activities
Cash From Financing Activities 0.000 200.3K
Net Change In Cash -142.1K 161.9K
YoY Change -187.76%
FREE CASH FLOW
Cash From Operating Activities -$142.1K -$38.36K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10003
CY2023Q1 dei City Area Code
CityAreaCode
917
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
599-1622
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
true
CY2023Q1 us-gaap Cash
Cash
373307
CY2022Q4 us-gaap Cash
Cash
515410
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
464500
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
415866
CY2023Q1 us-gaap Assets Current
AssetsCurrent
837807
CY2022Q4 us-gaap Assets Current
AssetsCurrent
931276
CY2023Q1 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
102375
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
204750
CY2023Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
219946528
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
217645818
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
220048903
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
217850568
CY2023Q1 us-gaap Assets
Assets
220886710
CY2022Q4 us-gaap Assets
Assets
218781844
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
24029
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2331
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
374990
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
300481
CY2023Q1 skgr Overfunding Loan
OverfundingLoan
5240000
CY2022Q4 skgr Overfunding Loan
OverfundingLoan
5240000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5639019
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5542812
CY2023Q1 skgr Deferred Underwriting And Advisory Fees
DeferredUnderwritingAndAdvisoryFees
7336000
CY2022Q4 skgr Deferred Underwriting And Advisory Fees
DeferredUnderwritingAndAdvisoryFees
7336000
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7336000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7336000
CY2023Q1 us-gaap Liabilities
Liabilities
12975019
CY2022Q4 us-gaap Liabilities
Liabilities
12878812
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11935361
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11643310
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-11934837
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11642786
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220886710
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
218781844
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
292051
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37032
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-292051
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-37032
CY2023Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2300710
CY2022Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
0
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2300710
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
2008659
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37032
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11642786
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2300710
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001912461
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
SK Growth Opportunities Corporation
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2023Q1 dei Entity File Number
EntityFileNumber
001-41432
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1643582
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
228 Park Avenue S #96693
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
2008659
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-11934837
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-8831
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37032
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-45863
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
2008659
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37032
CY2023Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2300710
CY2022Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
0
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-53741
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
21698
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3900
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
74509
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5231
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-142103
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38363
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
300000
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
99717
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
200283
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-142103
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
161920
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
515410
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
373307
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
161920
CY2023Q1 skgr Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
0
CY2022Q1 skgr Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
301365
CY2023Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2021-12-08
CY2022Q2 skgr Total Offering Costs In Connection Within Initial Public Offering
TotalOfferingCostsInConnectionWithinInitialPublicOffering
12000000
CY2022Q2 skgr Deferred Underwriting Commissions
DeferredUnderwritingCommissions
7000000
CY2022Q2 skgr Number Of Days Granted To Underwriters To Subscribe Shares Pursuant To Overallotment Option
NumberOfDaysGrantedToUnderwritersToSubscribeSharesPursuantToOverallotmentOption
P45D
CY2022Q2 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
214800000
CY2022Q2 skgr Per Share Value Of Restricted Asset
PerShareValueOfRestrictedAsset
10.25
CY2023Q1 skgr Businesscombinationconsummateperiodlimit
Businesscombinationconsummateperiodlimit
P185D
CY2023Q1 skgr Percentage Of Public Shares That Can Be Transferred Without Any Restriction
PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction
0.15
CY2023Q1 skgr Percentage Of Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2023Q1 skgr Period Within Which Business Combination Shall Be Consummated From The Consummation Of Initial Public Offer
PeriodWithinWhichBusinessCombinationShallBeConsummatedFromTheConsummationOfInitialPublicOffer
P18M
CY2023Q1 skgr Period Within Which Business Combination Shall Be Consummated From The Consummation Of Initial Public Offer If A Definitive Agreement Executed Relating To Business Combination
PeriodWithinWhichBusinessCombinationShallBeConsummatedFromTheConsummationOfInitialPublicOfferIfADefinitiveAgreementExecutedRelatingToBusinessCombination
P21M
CY2023Q1 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000
CY2023Q1 us-gaap Share Price
SharePrice
10.25
CY2023Q1 us-gaap Share Price
SharePrice
10.25
CY2023Q1 us-gaap Cash
Cash
373000
CY2023Q1 skgr Working Capital
WorkingCapital
4800000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. </div>
CY2023Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023Q1 skgr Restricted Investments Term
RestrictedInvestmentsTerm
P185D
CY2023Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
one to one
CY2023Q1 skgr Additional Time Frame For Completion Of Business Combination
AdditionalTimeFrameForCompletionOfBusinessCombination
three months each time for a total of up to 24 months
CY2023Q1 skgr Underwriting Discount Paid Per Unit
UnderwritingDiscountPaidPerUnit
0.2
CY2023Q1 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
4000000
CY2023Q1 skgr Deferred Underwriting Commission Per Unit
DeferredUnderwritingCommissionPerUnit
0.35
CY2023Q1 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
7000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
d320926d10q_htm.xml Edgar Link completed
0001193125-23-143597-index-headers.html Edgar Link pending
0001193125-23-143597-index.html Edgar Link pending
0001193125-23-143597.txt Edgar Link pending
0001193125-23-143597-xbrl.zip Edgar Link pending
d320926d10q.htm Edgar Link pending
d320926dex311.htm Edgar Link pending
d320926dex312.htm Edgar Link pending
d320926dex321.htm Edgar Link pending
d320926dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
skgr-20230331.xsd Edgar Link pending
skgr-20230331_def.xml Edgar Link unprocessable
skgr-20230331_cal.xml Edgar Link unprocessable
skgr-20230331_pre.xml Edgar Link unprocessable
skgr-20230331_lab.xml Edgar Link unprocessable